Cure My Disease

Don't miss your cure!

 Log in / Sign up

Global study tracks Real-World impact of new heart drug

NCT ID NCT07358078

Knowledge-focused Sponsor: Alnylam Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 10, 2026 · Updated 2 times

Summary

This study will follow about 2000 adults with a heart condition called ATTR-CM, where abnormal proteins build up and weaken the heart. Researchers want to see how patients do on a drug called vutrisiran in everyday medical care, not just in a controlled trial. They will measure symptoms, quality of life, and how often patients need hospital care over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Oct 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will include adult patients with ATTR-CM who, at enrollment, are either initiating treatment with vutrisiran or are initiating treatment with another approved ATTR-CM therapy.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has a diagnosis of ATTR-CM * Is initiating treatment with vutrisiran or another approved ATTR-CM therapy Exclusion Criteria: * Is enrolled in an interventional clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Transthyretin amyloidosis with cardiomyopathy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyloidosis cardiomyopathy wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Transthyretin amyloidosis with cardiomyopathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    24 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clinical Trial Site

    RECRUITING

    Tucson, Arizona, 85711, United States

  • Clinical Trial Site

    RECRUITING

    Beverly Hills, California, 90211, United States

  • Clinical Trial Site

    RECRUITING

    Naples, Florida, 34102, United States

  • Clinical Trial Site

    RECRUITING

    Kansas City, Kansas, 66160, United States

  • Clinical Trial Site

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Clinical Trial Site

    RECRUITING

    St Louis, Missouri, 63110, United States

  • Clinical Trial Site

    RECRUITING

    New Brunswick, New Jersey, 08901, United States

  • Clinical Trial Site

    RECRUITING

    Charlotte, North Carolina, 28270, United States

  • Clinical Trial Site

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Clinical Trial Site

    RECRUITING

    Memphis, Tennessee, 38120, United States

  • Clinical Trial Site

    RECRUITING

    Dallas, Texas, 75390, United States

  • Clinical Trial Site

    RECRUITING

    Heidelberg, Germany

  • Clinical Trial Site

    RECRUITING

    Munich, Germany

  • Clinical Trial Site

    RECRUITING

    Münster, Germany

  • Clinical Trial Site

    RECRUITING

    Bunkyō City, Japan

  • Clinical Trial Site

    RECRUITING

    Kumamoto, Japan

  • Clinical Trial Site

    RECRUITING

    Kurume, Japan

  • Clinical Trial Site

    RECRUITING

    Matsumoto, Japan

  • Clinical Trial Site

    RECRUITING

    Sendai, Japan

  • Clinical Trial Site

    RECRUITING

    Shinjuku, Japan

  • Clinical Trial Site

    RECRUITING

    Suita, Japan

  • Clinical Trial Site

    RECRUITING

    Tsukuba, Japan

  • Clinical Trial Site

    RECRUITING

    Ube, Japan

  • Clinical Trial Site

    RECRUITING

    Yufu, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.